Chroniques Génomiques - Les chimères du dépistage
MetadataAfficher la notice complète
The use of circulating tumour DNA to screen for cancer in asymptomatic individuals is the goal of Grail, initially set up by Illumina. This company is now raising a large amount of capital to develop this project on a much longer time scale than initially announced. Although it has access to cutting edge technology and is led by excellent scientists, the prospect for success in this application is rather bleak, mainly because of the extreme requirements for specificity in order to avoid overdiagnosis.
Pour citer ce document
Jordan, Bertrand ; Les chimères du dépistage : Chroniques Génomiques, Med Sci (Paris), , Vol. 33, N° 4 ; p. 441-444 ; DOI : 10.1051/medsci/20173304015